News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018

Medtronic Begins Pilot Study of Investigational Extravascular ICD System

Chronic study evaluating new ICD system designed to deliver pacing and defibrillation therapy via a lead placed under the sternum, outside the heart and veins

Medtronic Begins Pilot Study of Investigational Extravascular ICD System

August 9, 2018 — Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, with the first patient implant performed at Christchurch Hospital in New Zealand. The implant represents the first intended long-term patient use of the device, which is similar in size to transvenous ICDs.

“The Medtronic EV ICD system has the potential to deliver the benefits of traditional ICDs while eliminating the risks that can occur when leads are implanted inside the veins and heart,” said Ian Crozier, M.D., Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand, and principal investigator (PI) in the Medtronic Extravascular ICD Pilot Study. “We are incredibly pleased to contribute to this important research that will serve as a key step in establishing the safety and efficacy of this new approach.”

The pilot study will assess the Medtronic EV ICD system in 20 patients at four sites:

  • Christchurch Hospital (Crozier);
  • Austin Health in Heidelberg, Australia (PI: David O’Donnell, M.D.);
  • MonashHeart in Clayton, Australia (PI: Emily Kotschet, M.D.); and
  • The Prince Charles Hospital in Brisbane, Australia (PI: Haris Haqqani, M.D.).

After implantation of the system, patients and their devices will be routinely checked to assess safety and device performance.

The Medtronic EV ICD system is intended to provide the benefits of traditional transvenous ICDs including lifesaving defibrillation therapy, antitachycardia pacing to painlessly terminate arrhythmias, as well as post-shock pacing to protect from sudden cardiac death; and bradycardia pacing to address abnormally slow heart rates. It also is the same size (33 cc) and shape, and is expected to have similar longevity as traditional ICDs, but without any leads (thin wires) in the veins or heart. The investigational EV ICD device is implanted in the left mid-axillary region below the left armpit, and the newly designed lead is placed under the sternum (breastbone). New procedure tools guide the delivery of the system.

Medtronic research teams developed the EV ICD System and have completed multiple early research and acute feasibility studies using the system components, including the ASD1 (Acute Sensing and Defibrillation), SPACE2 (Substernal Pacing Acute Clinical Evaluation) and ASD23 studies.

Read the related article Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy

The EV ICD system is investigational and not approved for sale or distribution.

For more information: www.medtronic.com

References

1. Chan JYS, Lelakowski J, Murgatroyd FD et al. Novel Extravascular Defibrillation Configuration With a Coil in the Substernal Space: The ASD Clinical Study. J Am Coll Cardiol EP 2017;3:905-10.https://doi.org/10.1016/j.jacep.2016.12.026

2. Sholevar DP, Tung S, Kuriachan V, et al.  Feasibility of extravascular pacing with a novel substernal electrode configuration: The Substernal Pacing Acute Clinical Evaluation Study. Heart Rhythm. Published online 29Nov2017. DOI: http://dx.doi.org/10.1016/j.hrthm.2017.11.030

3. Boersma, LVA. Feasibility of Extravascular Pacing, Sensing And Defibrillation From A Novel Substernal lead: The Acute Extravascular Defibrillation, Pacing And Electrogram (ASD2) Study. Presented Heart Rhythm Society Scientific Sessions, May 11, 2018.

 


Related Content

News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — Providing medications for chronic diseases—for example, cholesterol-lowering, blood pressure and ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — The number of deaths and disabling strokes among patients at low surgical risk who were treated with ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — In the largest randomized trial conducted to compare minimally invasive and conventional cardiac ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

February 20, 2023 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home February 20, 2023
Home
News | Cardiovascular Clinical Studies

February 16, 2023 — Traffic noise may play an essential role in the development and deterioration of ischemic heart ...

Home February 16, 2023
Home
Subscribe Now